ACOTEC SCIEN.H. DL-00001 (7W3) - Total Assets
Based on the latest financial reports, ACOTEC SCIEN.H. DL-00001 (7W3) holds total assets worth €1.87 Billion EUR (≈ $2.18 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ACOTEC SCIEN.H. DL-00001 - Total Assets Trend (2021–2025)
This chart illustrates how ACOTEC SCIEN.H. DL-00001's total assets have evolved over time, based on quarterly financial data. Also see how much is ACOTEC SCIEN.H. DL-00001 worth for the company's overall valuation and market capitalisation.
ACOTEC SCIEN.H. DL-00001 - Asset Composition Analysis
Current Asset Composition (December 2025)
ACOTEC SCIEN.H. DL-00001's total assets of €1.87 Billion consist of 71.6% current assets and 28.4% non-current assets. Review ACOTEC SCIEN.H. DL-00001 balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 21.4% |
| Accounts Receivable | €220.49 Million | 11.8% |
| Inventory | €126.95 Million | 6.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €105.99 Million | 5.7% |
| Goodwill | €1.15 Million | 0.1% |
Asset Composition Trend (2021–2025)
This chart illustrates how ACOTEC SCIEN.H. DL-00001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ACOTEC SCIEN.H. DL-00001 (7W3) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ACOTEC SCIEN.H. DL-00001's current assets represent 71.6% of total assets in 2025, a decrease from 95.1% in 2021.
- Cash Position: Cash and equivalents constituted 21.4% of total assets in 2025, down from 87.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 11.8% of total assets.
ACOTEC SCIEN.H. DL-00001 Competitors by Total Assets
Key competitors of ACOTEC SCIEN.H. DL-00001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Stratec SE
XETRA:SBS
|
Germany | €408.98 Million |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
DRTECH Corporation
KQ:214680
|
Korea | ₩235.84 Billion |
|
Novacyt
PA:ALNOV
|
France | €40.28 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €62.52 Million |
ACOTEC SCIEN.H. DL-00001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.73 | 8.98 | 6.84 |
| Quick Ratio | 5.19 | 7.82 | 6.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.10 Billion | €1.08 Billion | €1.11 Billion |
ACOTEC SCIEN.H. DL-00001 - Advanced Valuation Insights
This section examines the relationship between ACOTEC SCIEN.H. DL-00001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.10 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 12.4% |
| Total Assets | €1.87 Billion |
| Market Capitalization | $198.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values ACOTEC SCIEN.H. DL-00001's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ACOTEC SCIEN.H. DL-00001's assets grew by 12.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ACOTEC SCIEN.H. DL-00001 (2021–2025)
The table below shows the annual total assets of ACOTEC SCIEN.H. DL-00001 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €1.87 Billion ≈ $2.18 Billion |
+12.36% |
| 2024-12-31 | €1.66 Billion ≈ $1.94 Billion |
+3.20% |
| 2023-12-31 | €1.61 Billion ≈ $1.88 Billion |
+14.22% |
| 2022-12-31 | €1.41 Billion ≈ $1.65 Billion |
+7.89% |
| 2021-12-31 | €1.31 Billion ≈ $1.53 Billion |
-- |
About ACOTEC SCIEN.H. DL-00001
Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with… Read more